Endothelin Receptor Blockade [BQ 123] in Acute ST-elevation Myocardial Infarction.

Trial Profile

Endothelin Receptor Blockade [BQ 123] in Acute ST-elevation Myocardial Infarction.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2014

At a glance

  • Drugs BQ 123 (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Apr 2014 Results published in the Thrombosis and Haemostasis.
    • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top